Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,958 total articles

Announced at Kaltura Connect on the Road 2026: IBM, Accenture, McDonald’s, Bank of America, Vanguard, Cisco, and More Are Among the Winners of this Year’s Kaltura Digital Engagement Awards

Announced at Kaltura Connect on the Road 2026: IBM, Accenture, McDonald’s, Bank of America, Vanguard, Cisco, and More Are Among the Winners of this Year’s Kaltura Digital Engagement Awards

Kaltura, a Nasdaq-listed agentic digital experience company, revealed the winners of its 2026 Digital Engagement Awards at the Kaltura Connect on the Road event series. The awards honor leading enterprises including IBM, Accenture, McDonald's, Bank of America, Vanguard, and Cisco for their innovative use of Kaltura's AI-powered digital engagement p…

Aduro Clean Technologies Announces Filing of Amended and Restated LIFE Offering Document Following Closing of Public Offering

Aduro Clean Technologies Announces Filing of Amended and Restated LIFE Offering Document Following Closing of Public Offering

Aduro Clean Technologies Inc. announced the filing of an amended and restated LIFE Offering document following the closing of its underwritten public offering. The offering involves the issuance of common shares to raise gross proceeds of approximately $7.17 million USD, subject to TSX final approval and customary conditions. The offering proceeds …

SunPower’s Cobalt Power Systems and Wunder Power Complete Advanced Solar System at San Francisco’s Waterfront Plaza

SunPower’s Cobalt Power Systems and Wunder Power Complete Advanced Solar System at San Francisco’s Waterfront Plaza

SunPower Inc., through its subsidiary Cobalt Power Systems, in partnership with Wunder Power, completed a 220.9 kW DC solar project at Waterfront Plaza, San Francisco, delivering approximately 349,000 kWh annually of clean electricity. The project demonstrates Cobalt’s capability to execute complex commercial solar installations in dense urban envi…

Genius Group Buys Back 6,600,000 Company Shares

Genius Group Buys Back 6,600,000 Company Shares

Genius Group Limited (NYSE American: GNS) announced it has repurchased 6.6 million Class A Ordinary Shares, representing 50% of its board-authorized share buyback mandate. The shares were bought below recent market prices and will be cancelled, reducing issued capital and increasing net asset value per share. The company plans further share reducti…

Kustom Entertainment Announces Major Ticket Inventory Updates for Country Stampede Kansas 2026 in Bonner Springs, Kansas

Kustom Entertainment Announces Major Ticket Inventory Updates for Country Stampede Kansas 2026 in Bonner Springs, Kansas

Kustom Entertainment announced a surge in ticket demand for the Country Stampede Kansas 2026 festival, with Thursday's single-day General Admission and Party Pit tickets sold out and rapid sales for Friday and Saturday tickets as well as 3-day passes. The company anticipates significant attendance from Park City and Wichita markets, supported by up…

Quantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense Platform

Quantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense Platform

Quantum Cyber has executed an exclusive worldwide license agreement with Project LightShift to integrate patented quantum photonic array technology into its AI-powered autonomous defense platform focused on drone warfare and national security. This strategic move solidifies Quantum Cyber's competitive quantum layer and aligns with the US government…

Dragonfly Energy Receives European Patent Allowance for Advancing Dry Electrode and Solid-State Battery Manufacturing

Dragonfly Energy Receives European Patent Allowance for Advancing Dry Electrode and Solid-State Battery Manufacturing

Dragonfly Energy Holdings Corp. announced it has received a European Patent Office allowance for its proprietary dry powder coating technology, key to its dry electrode manufacturing approach. This innovation supports scalable, solvent-free battery production and advances the company's all-solid-state battery development, reinforcing its intellectu…

Plains All American Pipeline and Plains GP Holdings Provide Updated Capital Spending Guidance for 2026

Plains All American Pipeline and Plains GP Holdings Provide Updated Capital Spending Guidance for 2026

Plains All American Pipeline and Plains GP Holdings announced an increased capital spending guidance for 2026, raising growth capital from approximately $350 million to between $400 million and $450 million. This increase is supported by multiple high-return growth projects primarily in the Permian Basin and Canadian gathering sectors. The company …

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for its investigational SkinJect® microneedle patch targeting basal cell carcinoma lesions in Gorlin Syndrome patients. This development follows a promising Phase 2 clinical trial and could accelerate regulatory approval pathways, offering a non-surgical treatment …

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Corporation appoints Andrew Gengos, former CFO of Terns Pharmaceuticals, as new Chief Financial Officer. Gengos brings over 25 years of leadership in biotech finance and business development. He will guide financial strategy as the company advances its lead oncology drug, atebimetinib, currently in Phase 3 trials targeting pancreatic ca…

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Nano Dimension Ltd. (Nasdaq: NNDM) announced a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company. The transaction will leverage Nano Dimension's Nasdaq listing and capital to accelerate growth in the healthcare AI sector. Infinite Epigenetics focuses on epigenetic diagnostics target…

Anfield Energy Announces a Key Milestone in Equipment Procurement, Advancing the Company Towards Hub-and-Spoke Production

Anfield Energy Announces a Key Milestone in Equipment Procurement, Advancing the Company Towards Hub-and-Spoke Production

Anfield Energy Inc. received the first custom-built underground haul truck from Young’s Machine Company, marking a key milestone in its equipment procurement program. This delivery supports the company’s uranium-vanadium mining operations in Utah and Colorado, advancing production under its hub-and-spoke model. Additionally, Anfield secured a new a…

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Dyadic International highlights growing interest in its proprietary C1 protein production platform driven by intensified Ebola virus outbreak preparedness and expanding commercial adoption across multiple markets. The platform's rapid development capabilities support expedited vaccine antigen and monoclonal antibody production, aligning with global…

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P immunotherapy in adjuvant mKRAS-driven pancreatic cancer did not meet the primary disease-free survival endpoint in the intent-to-treat population. However, post-hoc analyses revealed a significant benefit in patients with R0 resection, who represent the majority of the s…

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign

Seer, Inc.'s Board of Directors has issued a letter to shareholders ahead of the July 28, 2026 Annual Meeting, urging a vote in favor of the current board slate amid activist investor attempts to replace directors and push for a sale. The letter highlights Seer's pioneering leadership in proteomics technology, ongoing large-scale scientific studies…

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

Axsome Therapeutics presented new clinical data on its sleep disorder medicines AXS-12 and solriamfetol at SLEEP 2026, highlighting positive cognitive, functional, and quality-of-life outcomes in narcolepsy and obstructive sleep apnea patients. These presentations reinforce Axsome's leadership in central nervous system disorder treatments and its i…

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics announced the finalization of the SUNRISE-FA 2 pivotal trial protocol and statistical plan for its gene therapy candidate LX2006 in treating Friedreich Ataxia cardiomyopathy. The open-label study aims to support a Biologics License Application to the FDA under the accelerated approval pathway targeted for 2028. Enrollment is on t…